Wednesday 3 July 2024

The Pharma Letter Podcast — Episode 8 — Why hasn't the world embraced Sputnik V?

Biotechnology
Simon Wentworth
14 December 2021
kirill_dmitriev_rdif_podcast

More on this story...

Biotechnology
RDIF and AstraZeneca invest in aldosterone synthase inhibitor for arterial hypertension
1 February 2022
Pharmaceutical
Russia's Sputnik Light coronavirus vaccine approved in India
7 February 2022
Pharmaceutical
RDIF and Serum Institute agree manufacturing deal for Sputnik V
13 July 2021
Pharmaceutical
RDIF and UNICEF sign Sputnik V vaccine supply deal
27 May 2021


Related company news

Carvykti scores well in landmark CARTITUDE-4 study
China approval for Xtandi as prostate cancer therapy
Another win for nipocalimab as J&J closes in on rivals
FDA greenlight for Samsung Bioepis’ biosimilar to Stelara
More ones to watch >


Today's issue

Pharmaceutical
Access to medicines key to British voters, survey shows
3 July 2024
Generics
US authorities clear Mylan in long-running antitrust probe
3 July 2024
Biotechnology
Touchlight and LeninBio announce link up
3 July 2024
Pharmaceutical
Pentixapharm pads pipeline with strategic acquisition
3 July 2024
Biotechnology
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Biotechnology
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
Biotechnology
First COPD nod could add billions to Dupixent revenue
3 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Touchlight and LeninBio announce link up
3 July 2024
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
First COPD nod could add billions to Dupixent revenue
3 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze